COVID-19

Moderna COVID-19 booster clears FDA hurdle

The FDA will decide whether to authorize the boosters based off the advisory panel's recommendations.

Ocular adverse events linked to inactivated COVID-19 vaccine

A team of investigators at Cleveland Clinic Abu Dhabi studied patients who presented with ocular adverse events within 15 days after the first of 2 doses of the inactivated COVID-19 vaccine Sinopharm.

COVID-19: The Chinese experience early in the pandemic

Investigators find that long-term ocular complications require further observation.

Merck seeking FDA emergency use authorization for oral COVID-19 treatment

October 11, 2021

Merck and Ridgeback Biotherapeutics are seeking emergency use authorization for molnupiravir, an oral experimental antiviral treatment for mild-to-moderate COVID-19 in adults at risk for virus progression or hospitalization.

Autoantibodies in severe COVID-19: Possible culprits in long-term COVID-19 cases

September 24, 2021

Stanford University researchers released information indicating that in hospitalized patients with severe COVID-19, the virus can cause production of autoantibodies that can, in effect, cause the body to attack itself and result in inflammatory diseases.